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Abstract:

Results :

We conducted a genetic screen to
systematically identify molecular
determinants of S-phase DNA damage
response. We identified that NPRL2,
a subunit of the GATOR1 complex,
regulates S-DDR in an mTOR-pathwayindependent fashion. Loss of NPRL2
reduces CHK1 protein stability and leads to
defective S-DDR. NPRL2 deficiency
enhances anti-tumor immunity through
activation of DNA sensor STING-mediated
innate immune response. We identify that
NPRL2 is a key regulator of genome
maintenance and anti-tumor immunity.
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Introduction:

Figure 1. RPPA data analysis of KIRC TCGA data. DNA damage response and repair proteins
that are associated with NPRL2 (also known as TUSC4) protein expression.

Figure 2. KIRC TCGA genomic data analysis of NPRL2/PBRM1/SETD2/BAP1-deleted/mutated/deficient tumors. The comparison of NPRL2
deficiency with additional key tumor suppressor in KIRC

The GATOR1 complex functions as a
negative regulator of the mammalian
target of rapamycin complex 1
(mTORC1) by activating RagA GTPase
NPRL2 was a key mediator of
sensitivity to irinotecan treatment, a
topoisomerase I inhibitor, which
suggests a possible role in S-phase
DNA damage response.
Mismatch repair (MMR) deficiency
activates adaptive immune response
and predicts responses of tumors to
immune checkpoint blockade agents.
NPRL2 expression was significantly
lower in basal-like breast cancer
Reduced mRNA expression of NPRL2
correlated strongly with poor cancer
patient survival
In melanoma and renal carcinoma
studies, patients with low-NPRL2
expressing tumors showered better
response to immune checkpoint
blockade (PD-1/PD-L1)

Methods/Techniques:
Genomic Screening of S-Phase defective genes. 10169 genes
were used to generate irinotecan sensitivity gene signatures after
in-house normalization to average negative controls of each
plate, comparison between average of high and average of
medium/low cells lines were conducted to generate genomic
similarity with Pan-Cancer Irinotecan sensitivity marker
SLFN11.
Cell Culture. The breast and ovarian cancer cell lines
were kindly provided by Dr. Gordon B. Mills' laboratory. The
293T and HS578T cells were maintained in DMEM. The other
cell lines were maintained in RPMI1640 medium.
Multiplexed IHC staining. Tumor tissue from 4T1
underwent multiplexed immunofluorescence following the
manufacturer's instruction (PerkinElmer). The following
antibodies were used for IHC: anti-mouse PD-L1, anti-CD8, antiSTING, and anti-phospho-IRF3.
TIL scoring analysis and mutation load analysis. We analyzed
the correlation of NPRL2 mRNA level and the immune signature
scores and conducted FDR-based multiple testing correcting,
In Vivo Mouse Models. 4T1 breast cancer cells were
injected into the mammary pads of 6-8 weeks old female mice
per group. Tumor progression was monitored once per week.
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Figure 3. resentative multiplex-staining images from NPRL2-deficient mouse breast tumors. Representative images (Top) and quantitative analysis
(Bottom) of CD8 and PD-L1 (A), p-IRF3 and -H2AX (B), and Ki-67 and Caspase-3 (C) in control and NPRL2-deficient tumors with indicated treatments.
Data represent mean ± s.e.m. of three independent qPCR experiments; two-tailed t test. *p<0.05.

Discussion:
The data suggests that the effect of
NPRL2 on CHK1 protein stability is
independent of its role in regulating
mTOR signaling.
DNA replication, recombination, and
repair and cell cycle were among the
top networks of proteins interacting with
NPRL2, consistent with its role in SDDR.
Our findings demonstrate that NPRL2
deficiency promotes an innate immune
response, suggesting that NPRL2 could
determine immune responsiveness and
may predict responses to immune
checkpoint blockade in tumors with low
mutation load.
Results show that defective S-DDR as
a tumor-intrinsic mechanism
that activates the STING pathway and
sensitizes tumors to anti-PD-L1
treatment.
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Figure 4. (A) The establishment of NPRL2 stable knockdown cells in ccRCC cancer cell lines. qPCR (B) and ELISA (C) analysis of CCL5 and CXCL10
in control and NPRL2-deficient tumors with indicated treatments. Data represent mean ± s.e.m. of three independent qPCR experiments; twotailed t test. *p<0.05.
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